



US007053080B2

(12) **United States Patent**
Davis et al.

(10) **Patent No.:** **US 7,053,080 B2**
(45) **Date of Patent:** **May 30, 2006**

(54) **METHODS AND THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF OBESITY USING STEROL ABSORPTION INHIBITORS**

(75) Inventors: **Harry R. Davis**, Berkeley Heights, NJ (US); **Rudyard J. Ress**, Flemington, NJ (US); **John T. Strony**, Lebanon, NJ (US); **Enrico P. Veltri**, Princeton, NJ (US)

(73) Assignee: **Schering Corporation**, Kenilworth, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 295 days.

(21) Appl. No.: **10/247,397**

(22) Filed: **Sep. 19, 2002**

(65) **Prior Publication Data**

US 2003/0119428 A1 Jun. 26, 2003

Related U.S. Application Data

(63) Continuation-in-part of application No. 10/166,942, filed on Jun. 11, 2002.

(60) Provisional application No. 60/323,840, filed on Sep. 21, 2001.

(51) **Int. Cl.**

A61K 31/00 (2006.01)
A61K 31/7028 (2006.01)
A61K 31/397 (2006.01)
C07H 17/00 (2006.01)

(52) **U.S. Cl.** **514/210.02**; 514/23; 514/25; 514/449; 536/17.4

(58) **Field of Classification Search** 514/25, 514/23, 210.02, 449; 536/17.4

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,809,194 A 10/1957 Novello
3,108,097 A 10/1963 Ugi
3,152,173 A 10/1964 Ehrhart
3,267,104 A 8/1966 Hermans
3,399,192 A 8/1968 Regnier
3,692,895 A 9/1972 Nelson
3,716,583 A 2/1973 Nakamura
3,781,328 A 12/1973 Witte
3,948,973 A 4/1976 Phillips
4,072,705 A 2/1978 Mieville
4,075,000 A 2/1978 Abdulla
4,144,232 A 3/1979 Koppel
4,148,923 A 4/1979 Giudicelli
4,166,907 A 9/1979 Krapcho
4,178,695 A 12/1979 Erbeia
4,179,515 A 12/1979 Mieville
4,235,896 A 11/1980 Mieville

4,260,743 A 4/1981 Bose
4,304,718 A 12/1981 Kamiya
4,375,475 A 3/1983 Willard
4,443,372 A 4/1984 Luo
4,444,784 A 4/1984 Hoffiman
4,472,309 A 9/1984 Kamiya
4,479,900 A 10/1984 Luo
4,500,456 A 2/1985 Spitzer
4,534,786 A 8/1985 Luo
4,564,609 A 1/1986 Tamura
4,567,195 A 1/1986 Schwarz
4,576,748 A 3/1986 Greenlee
4,576,749 A 3/1986 Zahler
4,576,753 A 3/1986 Kamiya
4,581,170 A 4/1986 Mueller
4,595,532 A 6/1986 Miller
4,602,003 A 7/1986 Malinow
4,602,005 A 7/1986 Malinow
4,614,614 A 9/1986 Ernest
4,616,047 A 10/1986 Lafon
4,620,867 A 11/1986 Luo
4,626,549 A 12/1986 Molloy
4,633,017 A 12/1986 Mueller
4,642,903 A 2/1987 Davies
4,654,362 A 3/1987 Lommen
4,675,399 A 6/1987 Miller
4,680,289 A 7/1987 Applezweig
4,680,391 A 7/1987 Firestone
4,687,777 A 8/1987 Meguro et al.
4,739,101 A 4/1988 Bourgogne
4,778,883 A 10/1988 Yoshioka
4,784,734 A 11/1988 Torii
4,794,108 A 12/1988 Kishimoto
4,800,079 A 1/1989 Boyer
4,803,266 A 2/1989 Kawashima
4,814,354 A 3/1989 Ghebre-Sellassie
4,834,846 A 5/1989 Abramson
4,871,752 A 10/1989 Zermatter

(Continued)

FOREIGN PATENT DOCUMENTS

BE 884722 A 12/1980

(Continued)

OTHER PUBLICATIONS

The Merck Manual, 15th Edition, 1987, p. 953.*

(Continued)

Primary Examiner—James O. Wilson
Assistant Examiner—Ganapathy Krishnan
(74) *Attorney, Agent, or Firm*—Mark W. Russell; Ann Marie Cannoni

(57) **ABSTRACT**

The present invention provides methods for the treatment of obesity using sterol or 5 α -stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5 α -stanol absorption inhibitors and at least one obesity control medication.

U.S. PATENT DOCUMENTS					
			5,595,761 A	1/1997	Allen
4,876,365 A	10/1989	Kirkup	5,607,697 A	3/1997	Alkire
4,879,301 A	11/1989	Umio	5,612,353 A	3/1997	Ewing
4,895,726 A	1/1990	Curtet	5,612,367 A	3/1997	Timko
4,925,672 A	5/1990	Gremm	5,612,378 A	3/1997	Tianbao
4,937,267 A	6/1990	Holloway	5,618,707 A	4/1997	Homann
4,939,248 A	7/1990	Yoshioka	5,622,719 A	4/1997	Myers
4,952,689 A	8/1990	Kawashima	5,622,985 A	4/1997	Olukotun
4,961,890 A	10/1990	Boyer	5,624,920 A	4/1997	McKittrick
4,983,597 A	1/1991	Yang	5,627,176 A	5/1997	Kirkup
4,990,535 A	2/1991	Cho	5,631,023 A	5/1997	Kearney
5,021,461 A	6/1991	Robinson et al.	5,631,365 A	5/1997	Rosenblum
5,030,628 A	7/1991	Joyeau	5,633,246 A	5/1997	McKittrick
5,073,374 A	12/1991	McCarty	5,635,210 A	6/1997	Allen
5,091,525 A	2/1992	Brennan	5,639,475 A	6/1997	Bettman
5,093,365 A	3/1992	Berge	5,639,739 A	6/1997	Dominguez
5,099,034 A	3/1992	Yoshida	5,656,624 A	8/1997	Vaccaro
5,100,675 A	3/1992	Cho	5,661,145 A	8/1997	Davis
5,106,833 A	4/1992	Broze	5,674,893 A	10/1997	Behounek
5,110,730 A	5/1992	Edgington	5,688,785 A	11/1997	Vaccaro
5,112,616 A	5/1992	McCarty	5,688,787 A	11/1997	Burnett
5,120,713 A	6/1992	Mugica	5,688,990 A	11/1997	Shankar
5,120,729 A	6/1992	Chabala	5,691,375 A	11/1997	Behounek
5,130,333 A	7/1992	Pan	5,698,527 A	12/1997	Kim
5,145,684 A	9/1992	Liversidge	5,698,548 A	12/1997	Dugar
5,157,025 A	10/1992	Aberg	5,703,188 A	12/1997	Mandeville
5,162,117 A	11/1992	Stupak	5,703,234 A	12/1997	Iwasaki
5,178,878 A	1/1993	Wehling	5,709,886 A	1/1998	Bettman
5,188,825 A	2/1993	Iles	5,718,388 A	2/1998	Czekai
5,190,970 A	3/1993	Pan	5,728,827 A	3/1998	Kannapan
5,204,461 A	4/1993	Murayama	5,734,077 A	3/1998	Regnier
5,219,574 A	6/1993	Wehling	5,739,321 A	4/1998	Wu
5,223,264 A	6/1993	Wehling	5,744,467 A	4/1998	McKittrick
5,229,362 A	7/1993	Kirst	5,747,001 A	5/1998	Wiedmann
5,229,381 A	7/1993	Doherty	5,753,254 A	5/1998	Khan
5,229,510 A	7/1993	Knight	5,756,470 A	5/1998	Yumibe
5,260,305 A	11/1993	Dennick	5,759,865 A	6/1998	Bruns
5,278,176 A	1/1994	Lin	5,767,115 A	6/1998	Rosenblum
H1286 H	2/1994	Eisman et al.	5,776,491 A	7/1998	Allen
5,286,631 A	2/1994	Boeck	5,783,582 A *	7/1998	Guo et al. 514/278
5,298,497 A	3/1994	Tschollar	5,807,576 A	9/1998	Allen
5,306,817 A	4/1994	Thiruvengadam	5,807,577 A	9/1998	Ouali
5,318,767 A	6/1994	Liversidge	5,807,578 A	9/1998	Acosta-Cuello
5,348,953 A	9/1994	Doherty	5,807,834 A	9/1998	Morehouse
5,350,868 A	9/1994	Yoshida	5,808,056 A	9/1998	Amato
5,358,852 A	10/1994	Wu	5,817,806 A	10/1998	Rossi
5,384,124 A	1/1995	Courteille	5,827,536 A	10/1998	Laruelle
5,385,885 A	1/1995	Gasic	5,827,541 A	10/1998	Yarwood
5,399,363 A	3/1995	Liversidge	5,831,091 A	11/1998	Ohmizu
5,401,513 A	3/1995	Wehling	5,843,984 A	12/1998	Clay
5,412,092 A	5/1995	Rey	5,846,966 A *	12/1998	Rosenblum et al. ... 514/210.02
5,429,824 A	7/1995	June	5,847,008 A	12/1998	Doebber
5,446,464 A	8/1995	Feldle	5,847,115 A	12/1998	Iwasaki
5,461,039 A	10/1995	Tschollar	5,851,553 A	12/1998	Myers
5,464,632 A	11/1995	Cousin	5,856,473 A	1/1999	Shankar
5,494,683 A	2/1996	Liversidge	5,858,409 A	1/1999	Karetny
5,503,846 A	4/1996	Wehling	5,859,051 A	1/1999	Adams
5,510,118 A	4/1996	Bosch	5,862,999 A	1/1999	Czekai
5,510,466 A	4/1996	Krieger	5,866,163 A	2/1999	Myers
5,518,187 A	5/1996	Bruno	5,869,098 A	2/1999	Misra
5,518,738 A	5/1996	Eickhoff	5,871,781 A	2/1999	Myers
5,545,628 A	8/1996	Deboeck	5,880,148 A	3/1999	Edgar
5,550,229 A	8/1996	Iwasaki	5,883,109 A	3/1999	Gregg
5,552,160 A	9/1996	Liversidge	5,886,171 A	3/1999	Wu
5,561,227 A	10/1996	Thiruvengadam	5,919,672 A	7/1999	Homann
5,563,264 A	10/1996	Kume	5,925,333 A	7/1999	Krieger
5,567,439 A	10/1996	Myers	5,952,003 A	9/1999	Guentensberger
5,576,014 A	11/1996	Mizumoto	5,952,321 A	9/1999	Doherty
5,587,172 A	12/1996	Cherukuri	5,959,123 A	9/1999	Singh
5,587,180 A	12/1996	Allen	5,972,389 A	10/1999	Shell
			5,976,570 A	11/1999	Greaves

5,994,554	A	11/1999	Kliewer	DE	2046823	A	3/1972
5,998,441	A	12/1999	Palkowitz	DE	2521113	A	3/1976
6,008,237	A	12/1999	Sahoo	EP	0002151	A1	5/1979
6,027,747	A	2/2000	Terracol	EP	0002151	B1	5/1979
6,028,109	A	2/2000	Wilson	EP	0010299	B1	2/1984
6,030,990	A	2/2000	Maeda et al.	EP	0179559	A2	4/1986
6,033,656	A	3/2000	Mikami	EP	0199630	A1	10/1986
6,040,147	A	3/2000	Ridker	EP	0264231	A1	4/1988
6,043,257	A	3/2000	Dominguez	EP	0266896	B1	5/1988
6,056,975	A	5/2000	Mitra	EP	0274873	B1	7/1988
6,057,342	A	5/2000	Fevig	EP	0288973	B1	11/1988
6,063,764	A	5/2000	Creasey	EP	0311366	B1	4/1989
6,066,653	A	5/2000	Gregg	EP	0333268	A1	9/1989
6,071,899	A	6/2000	Hickey	EP	0337549	A1	10/1989
6,074,670	A	6/2000	Stamm	EP	0365364	A2	4/1990
6,080,767	A	6/2000	Klein	EP	0369686	A1	5/1990
6,080,778	A	6/2000	Yankner	EP	0375527	A1	6/1990
6,084,082	A	7/2000	Ravikumar	EP	0199630	B1	9/1990
6,090,830	A	7/2000	Myers	EP	0401705	A3	12/1990
6,090,839	A	7/2000	Adams	EP	0415487	A2	3/1991
6,093,812	A	7/2000	Thiruvengadam	EP	0455042	A1	11/1991
6,096,883	A	8/2000	Wu	EP	0457514	A1	11/1991
6,099,865	A	8/2000	Augello	EP	0461548	A3	12/1991
6,103,705	A	8/2000	Uzan	EP	0462667	A2	12/1991
6,110,493	A	8/2000	Guentensberger	EP	0475148	A1	3/1992
6,117,429	A	9/2000	Bucci	EP	0475755	B1	3/1992
6,121,319	A	9/2000	Somers	EP	0481671	A1	4/1992
6,127,424	A	10/2000	Martin	EP	0482498	A3	4/1992
6,133,001	A	10/2000	Homann	EP	0524595	A1	1/1993
6,139,873	A	10/2000	Hughes	EP	0337549	B1	10/1995
6,140,354	A	10/2000	Dax	EP	0720599	B1	7/1996
6,143,885	A	11/2000	Choi	EP	0457514	B1	8/1996
6,147,090	A	11/2000	DeNinno	EP	0 753 298	A1	1/1997
6,147,108	A *	11/2000	Hauptman 514/449	EP	0793958	A2	9/1997
6,147,109	A	11/2000	Liao	EP	0814080	A1	12/1997
6,147,250	A	11/2000	Somers	EP	0904781	A2	3/1999
6,159,997	A	12/2000	Tsujita	EP	1 036 563	A1	9/2000
6,162,805	A	12/2000	Hefi	EP	1048295	A2	11/2000
6,166,049	A	12/2000	Smith et al.	FR	1103113		10/1955
6,174,665	B1	1/2001	Dullien	FR	2779347		12/1997
6,180,138	B1	1/2001	Engh	GB	861367		2/1961
6,180,625	B1	1/2001	Persson	GB	902658		8/1962
6,180,660	B1	1/2001	Whitney	GB	1415295		11/1975
6,191,117	B1	2/2001	Kozachuk	GB	2329334	A	3/1999
6,191,159	B1	2/2001	Pinto	JP	136485		5/1981
6,200,998	B1	3/2001	Sahoo	JP	028057		10/1981
6,207,697	B1	3/2001	Han	JP	180212		3/1986
6,207,699	B1	3/2001	Rothman	JP	121479		12/1986
6,207,822	B1	3/2001	Thiruvengadam	JP	61280295	A	12/1986
6,214,831	B1	4/2001	Yokoo	JP	219681		4/1987
6,235,706	B1	5/2001	Gould	JP	63017859	A	1/1988
6,242,605	B1	6/2001	Raveendranath	JP	91068020		10/1991
6,245,743	B1	6/2001	Marlowe	JP	4054182	A	2/1992
6,248,781	B1	6/2001	Jeppesen	JP	4266869	A	9/1992
6,251,852	B1	6/2001	Gould	JP	4356195	A	12/1992
6,262,042	B1	7/2001	Cook	JP	4356495		12/1992
6,262,047	B1	7/2001	Zhu	JP	5058993	A	3/1993
6,262,098	B1	7/2001	Huebner	JP	5194209	A	8/1993
6,277,584	B1	8/2001	Chu	JP	5239020	A	9/1993
6,316,029	B1	11/2001	Jain	JP	94047573		6/1994
RE37,721	E	5/2002	Rosenblum	JP	95051558	B2	6/1995
2001/0028895	A1	10/2001	Bisgaier et al.	WO	WO 82/01649		5/1982
2002/0006919	A1	1/2002	Thosar	WO	WO 87/04429		7/1987
2002/0039774	A1	4/2002	Kramer et al.	WO	WO 88/04656		6/1988
2002/0128252	A1	9/2002	Glombik et al.	WO	WO 88/05296		7/1988
2002/0128253	A1	9/2002	Glombik et al.	WO	WO 98/47518		10/1988
2002/0132855	A1	9/2002	Nelson et al.	WO	WO 91/03249		3/1991
2002/0137689	A1	9/2002	Glombik et al.	WO	WO 92/13837		8/1992
2003/0153541	A1	8/2003	Dudley et al.	WO	WO 93/02048		2/1993
				WO	WO 93/07167		4/1993
				WO	WO 93/11150		6/1993

FOREIGN PATENT DOCUMENTS

US 7,053,080 B2

WO	WO 94/17038	8/1994	WO	WO 00/38722	7/2000
WO	WO 94/20535	9/1994	WO	WO 00/38723	7/2000
WO	WO 94/26738	11/1994	WO	WO 00/38724	7/2000
WO	WO 95/04533	2/1995	WO	WO 00/38725	7/2000
WO	WO 95/06470	3/1995	WO	WO 00/38726	7/2000
WO	WO 95/08532	3/1995	WO	WO 00/38727	7/2000
WO	WO 95/18143	7/1995	WO	WO 00/38728	7/2000
WO	WO 95/26334	10/1995	WO	WO 00/38729	7/2000
WO	WO 95/28919	11/1995	WO	WO 00/40247	7/2000
WO	WO 95/35277	12/1995	WO	WO 00/45817	8/2000
WO	WO 96/00288	1/1996	WO	WO 00/50392	8/2000
WO	WO 96/09827	4/1996	WO	WO 00/53149	9/2000
WO	WO 96/16037	5/1996	WO	WO 00/53173	9/2000
WO	WO 96/19450	6/1996	WO	WO 00/53563	9/2000
WO	WO 96/19987	7/1996	WO	WO 00/56403	9/2000
WO	WO 96/40255	12/1996	WO	WO 00/57859	10/2000
WO	WO 97/16455	5/1997	WO	WO 00/57918	10/2000
WO	WO 97/18304	5/1997	WO	WO 00/60107	10/2000
WO	WO 97/21676	6/1997	WO	WO 00/63153	10/2000
WO	WO 97/25042	7/1997	WO	WO 00/63161	10/2000
WO	WO 97/28149	8/1997	WO	WO 00/63190	10/2000
WO	WO 97/31907	9/1997	WO	WO 00/63196	10/2000
WO	WO 97/35576	10/1997	WO	WO 00/63209	10/2000
WO	WO 97/41098	11/1997	WO	WO 00/63703	10/2000
WO	WO 97/46238	12/1997	WO	WO 00/69412	11/2000
WO	WO 98/01100	1/1998	WO	WO 00/69445	11/2000
WO	WO 98/05331	2/1998	WO	WO 00/72825	12/2000
WO	WO 98/14179	4/1998	WO	WO 00/72829	12/2000
WO	WO 98/31360	7/1998	WO	WO 00/75103	12/2000
WO	WO 98/31361	7/1998	WO	WO 00/76482	12/2000
WO	WO 98/31366	7/1998	WO	WO 00/76488	12/2000
WO	WO 98/43081	10/1998	WO	WO 00/78312	12/2000
WO	WO 98/46215	10/1998	WO	WO 00/78313	12/2000
WO	WO 98/57652	12/1998	WO	WO 01/00579	1/2001
WO	WO 99/06035	2/1999	WO	WO 01/00603	1/2001
WO	WO 99/06046	2/1999	WO	WO 01/08686	2/2001
WO	WO 99/08501	2/1999	WO	WO 01/12176	2/2001
WO	WO 99/09967	3/1999	WO	WO 01/12187	2/2001
WO	WO 99/11260	3/1999	WO	WO 01/12612	2/2001
WO	WO 99/12534	3/1999	WO	WO 01/14349	3/2001
WO	WO 99/04815	4/1999	WO	WO 01/14350	3/2001
WO	WO 99/15159	4/1999	WO	WO 01/14351	3/2001
WO	WO 99/15520	4/1999	WO	WO 01/15744	3/2001
WO	WO 99/18072	4/1999	WO	WO 01/16120	3/2001
WO	WO 99/20275	4/1999	WO	WO 01/17994	3/2001
WO	WO 99/20614	4/1999	WO	WO 01/18210	3/2001
WO	WO 99/22728	5/1999	WO	WO 01/21181	3/2001
WO	WO 99/29300	6/1999	WO	WO 01/21259	3/2001
WO	WO 99/38498	8/1999	WO	WO 01/21578	3/2001
WO	WO 99/38845	8/1999	WO	WO 01/21647	3/2001
WO	WO 99/38850	8/1999	WO	WO 01/22962	4/2001
WO	WO 99/46232	9/1999	WO	WO 01/25225	4/2001
WO	WO 99/47123	9/1999	WO	WO 01/25226	4/2001
WO	WO 99/48488	9/1999	WO	WO 01/30343	5/2001
WO	WO 99/66929	12/1999	WO	WO 01/32161	5/2001
WO	WO 99/66930	12/1999	WO	WO 01/34148	5/2001
WO	WO 00/04011	1/2000	WO	WO 01/35970	5/2001
WO	WO 00/07617	2/2000	WO	WO 01/40192	6/2001
WO	WO 00/16749	3/2000	WO	WO 01/45676	6/2001
WO	WO 00/18395	4/2000	WO	WO 01/49267	7/2001
WO	WO 00/20623	4/2000	WO	WO 01/60807	8/2001
WO	WO 00/23415	4/2000	WO	WO 01/64221	9/2001
WO	WO 00/23416	4/2000	WO	WO 01/76632	10/2001
WO	WO 00/23425	4/2000	WO	WO 01/96347	12/2001
WO	WO 00/23445	4/2000	WO	WO 02/08188	1/2002
WO	WO 00/23451	4/2000	WO	WO 02/26729	4/2002
WO	WO 00/28981	5/2000	WO	WO 02/026729	4/2002
WO	WO 00/31548	6/2000	WO	WO 02/50027	6/2002
WO	WO 00/32189	6/2000	WO	WO 02/50060	6/2002
WO	WO 00/34240	6/2000	WO	WO 02/50068	6/2002
WO	WO 00/37057	6/2000	WO	WO 02/50090	6/2002

WO	WO 02/058731	8/2002
WO	WO 02/058732	8/2002
WO	WO 02/058733	8/2002
WO	WO 02/058734	8/2002
WO	WO 02/064094	8/2002
WO	WO 02/064130	8/2002
WO	WO 02/064549	8/2002
WO	WO 02/064664	8/2002
WO	WO 02/072104	9/2002
WO	WO 02/081454	10/2002
WO	WO 03/018024	3/2003
WO	WO 03/018059	3/2003
WO	WO 03/039542	5/2003
WO	WO 03/074101	9/2003
WO	WO 03/088962	10/2003

OTHER PUBLICATIONS

Health Education Associates, 1996.*

Castaner, R.M. et al, *Drugs of the Future*, 2000, 25(7), 679-685.*

Vaccaro, W.D. et al, "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar" *Bioorganic & Medicinal Chemistry Ltrs., Oxford, G.B.*, 8:313-318 (1998).

Vaccaro, W.D. et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors", *Bioorganic & Medicinal Chem. Ltrs. Oxford, G.B.* 8:319-322 (1998).

H. Davis et al., "Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in Apo E Knockout Mice", *Arterioscler, Thromb. Vasc. Biol* 21:2032-2038, (Dec. 2001).

Simova, E., "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", *Chemical Abstracts* No. 15, 86 (Apr. 11, 1997).

Otto et al., Stereochemistry of dehydration and halogenation of α R* and α S* isomeric 3-(α -hydroxybenzyl)-1,4-diphenyl-2 azetidinones, *Chemical Abstracts* No. 19, 99 (Nov. 7, 1983).

T. Durst et al, "Metallation of N-Substituted β -Lactams. A Method of the Introduction of 3-substituents into β -Lactams" *Canadian Journal of Chemistry*, 50:3196-3201 (1971).

Nobuki, O. et al., "Stereoselective syntheses of β -lactam derivatives by ultrasound promoted Reformatskii reaction" *Chemical Abstracts* No. 106, 17 (Apr. 27, 1987).

M. Hoekman, et al., "Synthesis of Homologues of 4,5-Dihydroxy-and 4-Hydroxy-5-oxohexanoic Acid γ -Lactones", *J. Agric. Food Chem.*, 30:920-924 (1982).

H. Otto et al. "Darstellung und Stereochemie von 3-(α -Hydroxybenzyl)-1,4-diphenyl-2-azetidinonen", *Liebigs Ann. Chem.* 1152-1161 (1983).

G. George et al. "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" *Tetrahedron Letters*, 26:3903-3906 (1985).

Hart et al. "An Enantioselective Approach to Carbapenem Antibodies: Formal Synthesis of (+)-Thienamycin", *26 Tetrahedron Letters*, 45:5493-5496 (1985).

Panfil, I. et al. "Synthesis of β -Lactams from α , β -Unsaturated Sugar δ -Lactones" *24 Heterocycles* 6:1609-1617 (1986).

D. Roger Illingworth, "An Overview of Lipid-Lower Drugs" *Drugs* 36:63-71 (1988).

Joseph L. Witztum, M.D., "Current Approaches to Drug Therapy for the Hypercholesterolemic Patient" *Circulation* 80:1101-1114 (1989).

D. B. ... et al. "Dietary ..."

Schnitzer-Polokoff, R. et al., "Effects of Acyl-CoA: Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" *Comp. Biochem. Physiol.* 99A:665-670 (1991).

Horie, M. et al, "Hypolipidemic effects of NB-598 in dogs" *Atherosclerosis* 88:183-192 (1991).

Baxter, A., "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo", *The Journal of Biological Chemistry* 267:11705-11708 (1992).

Summary Factfile, "Anti-Atherosclerotic Agents" *Current Drugs Ltd.* (1992).

Harwood H. James, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β -tiginogenin cellobioside (CP-88818; tiqueside) 1" *Journal of Lipid Research* 34:377-395 (1993).

Salisbury, B. et al., "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" *Atherosclerosis* 115:45-63 (1995).

Clader, J. W. et al., "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Vivo Activity" *Journal of Medicinal Chemistry* 38:1600-1607 (1995).

Sybertz, E., "Sch 48461, a novel inhibitor of cholesterol absorption" *Atherosclerosis* pp. 311-315 (1995).

Vaccaro, W, et al, "2-Azetidinone Cholesterol Absorption Inhibitors; Increased Potency by Substitution of the C-4 Phenyl Ring", *Bioorg. & Med. Chem.* 6:1429-1437 (1998).

G. Wu et al, A Novel One-Step Diastereo-and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors A.C.S. (Apr. 21, 1999).

B. Staels, "New Roles for PPARs in Cholesterol Homeostasis", *Trends in Pharmacological Sciences*, 22:9 p. 444 (Sep. 2001).

Abbott et al, "Tricor® Capsules, Micronized", *Physicians Desk Reference*, Jan. 8, 2001.

M. Feher et al., 1991, *Lipids and Lipid Disorders*, p. 1-87 (1991).

M. Ricote et al., "New Roles for PPARs in Cholesterol Homeostasis", *Trends in Pharmacological Science*, vol. 22, No. 9 441-443 (2001).

C. Dujovne et al, "Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a multicenter Dose-Ranging Study", *J. Clin., Pharm.* 41:170-78 (Jan. 2001).

W. Oppolzer et al., "Asymmetric Diels—Alder Reactions, Facile Preparation and Structure of Sulfonamido—Isobornyl Acrylates", *Tetrahedron Letters* No. 51, 25:5885-5888 (1984).

M. Davidson et al., "Colesevelam Hydrochloride: a non-absorbed, polymeric cholesterol lowering agent", *Expert Opinion Investigating Drugs*, 11:2663-71, (Nov. 2000).

M. Davidson et al., "Colesevelam hydrochloride (cholestagel): a new, potent bileacid sequestrant associated with a low incidence of gastrointestinal effects", *159 Arch. Intern. Med.* 16 1893-900 (Sep. 1999).

I. Wester, "Cholesterol—Lowering effect of plant sterols", *Euro. J.Lipid, Sci. Tech.* 37-44 (2000).

A. Andersson et al., "Cholesterol-lowering effects of a stanol ester-containing low fat margarine used in conjunction with a diet low in saturated fat", *J. Food Sci.*

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.